The surge in the interest in personalized medicine necessitates a corresponding rational approach for implementing such individualized therapies. Dynamiceuticals represents a natural extension of the Pharmaceutical and Electroceutical fields, where the precise determination of the dynamical regimes of the pathophysiology will guide to devise therapies that ameliorate the pathology in a well-con...

We live in the era of genomics and big data. Evaluating the impact on health of large-scale biological, social, and environmental data is an emerging challenge in the field of epidemiology. In the past 3 years, major discussions and plans for the future of epidemiology, including with several recommendations for actions to transform the field, have been launched by 2 institutes within the Natio...

For our participation at the clinical trials task in the TREC 2017 Precision Medicine track 2017, we investigated retrieving and matching clinical trial documents with patient information based on text and concept annotations of the text, filtering results for demographic information such as gender and age, and re-ranking results based on patient information. Experimental results show a competi...

Institute of Medicine. Initial national priori1. ties for comparative effectiveness research. Washington, DC: Institute of Medicine, 2009. Iglehart JK. Health insurers and medical2. imaging policy — a work in progress. N Engl J Med 2009;360:1030-7. Avorn J. Debate about funding compara3. tive-effectiveness research. N Engl J Med 2009;360:1927-9. Garber AM, Tunis SR. Does comparative4. effective...

The ability to quickly analyze, separate, and manipulate multiple types of biomarkers from small sample volumes is a significant step toward personalized medicine.

The regulatory demarcations between clinical research and quality improvement (QI) are ambiguous and controversial. Some projects that were undertaken as a form of QI were deemed by regulatory agencies to be research and thus to require institutional review board approval. In the era of personalized medicine, some physicians may ask some patients to participate in n-of-1 trials in an effort to ...

The confluence of therapeutics and diagnostics based on the advantages of nanotechnology offers significant opportunities for personalized and precision medicine. Intelligent nanotheranostics based on bioresponsive systems have recently emerged and offer the promise of high specificity and efficiency via "on-demand" activation of both therapeutic and diagnostic capabilities.